Koyfin Home > Directory > Health Care > Antares Pharma > EBITDA

Antares Pharma EBITDA Chart (ATRS)

Antares Pharma annual/quarterly EBITDA from 2000 to 2018. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Antares Pharma EBITDA for the quarter ending December 12, 2018 was $-5m a 1.88% decrease of 0m year over year
  • Antares Pharma EBITDA for the last 12 months ending December 12, 2018 was $-14m a -6.34% increase of 1m year over year
  • Antares Pharma Annual EBITDA for 2018 was $-14m a -1.10% increase of 0m from 2017
  • Antares Pharma Annual EBITDA for 2017 was $-14m a -55.13% increase of 8m from 2016
  • Antares Pharma Annual EBITDA for 2016 was $-22m a 15.12% decrease of -3m from 2015
Other Income Statement Metrics:
  • Antares Pharma Net Income for the quarter ending December 12, 2018 was $6m a 200.96% increase of 12m year over year
  • Antares Pharma Total Revenue for the quarter ending December 12, 2018 was $19m a 32.51% increase of 6m year over year
View Chart On Koyfin

Quarterly ATRS EBITDA Data

12/2018$-5m
09/2018$-1m
06/2018$-3m
03/2018$-5m
12/2017$-3m
09/2017$-4m
06/2017$-2m
03/2017$-4m
12/2016$-4m
09/2016$-6m

Annual ATRS EBITDA Data

2018$-14m
2017$-14m
2016$-22m
2015$-19m
2014$-34m
2013$-20m
2012$-11m
2011$-4m
2010$-6m
2009$-9m